Baidu
map

Acta Neurol Scand:缺血性卒中患者的健康预后及花费

2015-09-28 phylis 译 MedSci原创

目的:随着发展,卒中的死亡率下降。然而,对患者的健康相关生活质量(HRQoL),质量校正生存时间(QALYs)以及花费了解较少。研究人员应用芬兰地区十年前收集的两个数据集来分析这些情况。方法:两个研究(Study1:1989-1991,Study2:2001-2003)中共有468和355名首发缺血性卒中的患者,对其随访一年。比较病例致死率,15D测量的 HRQoL, QALYs,花费及第一年花费

目的:随着发展,卒中的死亡率下降。然而,对患者的健康相关生活质量(HRQoL),质量校正生存时间(QALYs)以及花费了解较少。研究人员应用芬兰地区十年前收集的两个数据集来分析这些情况。

方法:两个研究(Study1:1989-1991,Study2:2001-2003)中共有468和355名首发缺血性卒中的患者,对其随访一年。比较病例致死率、15D测量的 HRQoL、 QALYs、花费及第一年花费/ QALYs。应用回归分析检测各种因素对QALYs的影响。

结果:在后来的研究中,病例死亡率下降,平均15D分数升高。在随访期间,在Study1和Study2中,患者的QALY的均值分别为0.519(95% CI 0.453-0.555),0.646(95% CI 0.613-0.680)。年龄,卒中前mRS,急性期Scandinavian卒中量表,以及不同研究组解释QALYs的变异。Study1和Study2的第一年平均总花费分别是10626欧,14603欧以及平均花费/QALY分别为20474欧,22605欧。与Study1相比,无患者特征标准化的Study2的增量成本效益比是31315欧,患者特征标准化后的为60684欧。

结论:卒中患者预后的改善是明确的,但是哪种程度上是由于治疗的进展而改善的还不清楚。需要更多的试验研究卒中治疗的成本效益。

原文出处:

Puumalainen A, Numminen H, Elonheimo O,et al.Health outcomes and costs of ischemic stroke patients in Finland.Acta Neurol Scand. 2015 Sep 22.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999571, encodeId=4d2a19995e137, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 27 20:15:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720062, encodeId=7b931e2006261, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jan 25 20:15:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849514, encodeId=937018495140f, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Oct 18 21:15:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010330, encodeId=5bb12010330f1, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 31 05:15:00 CST 2016, time=2016-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806035, encodeId=2c0118060359f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 02 12:15:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892684, encodeId=957a1892684b8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 18 13:15:00 CST 2016, time=2016-07-18, status=1, ipAttribution=)]
    2016-04-27 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999571, encodeId=4d2a19995e137, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 27 20:15:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720062, encodeId=7b931e2006261, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jan 25 20:15:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849514, encodeId=937018495140f, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Oct 18 21:15:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010330, encodeId=5bb12010330f1, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 31 05:15:00 CST 2016, time=2016-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806035, encodeId=2c0118060359f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 02 12:15:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892684, encodeId=957a1892684b8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 18 13:15:00 CST 2016, time=2016-07-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999571, encodeId=4d2a19995e137, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 27 20:15:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720062, encodeId=7b931e2006261, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jan 25 20:15:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849514, encodeId=937018495140f, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Oct 18 21:15:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010330, encodeId=5bb12010330f1, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 31 05:15:00 CST 2016, time=2016-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806035, encodeId=2c0118060359f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 02 12:15:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892684, encodeId=957a1892684b8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 18 13:15:00 CST 2016, time=2016-07-18, status=1, ipAttribution=)]
    2015-10-18 windight
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999571, encodeId=4d2a19995e137, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 27 20:15:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720062, encodeId=7b931e2006261, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jan 25 20:15:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849514, encodeId=937018495140f, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Oct 18 21:15:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010330, encodeId=5bb12010330f1, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 31 05:15:00 CST 2016, time=2016-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806035, encodeId=2c0118060359f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 02 12:15:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892684, encodeId=957a1892684b8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 18 13:15:00 CST 2016, time=2016-07-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1999571, encodeId=4d2a19995e137, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 27 20:15:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720062, encodeId=7b931e2006261, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jan 25 20:15:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849514, encodeId=937018495140f, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Oct 18 21:15:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010330, encodeId=5bb12010330f1, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 31 05:15:00 CST 2016, time=2016-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806035, encodeId=2c0118060359f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 02 12:15:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892684, encodeId=957a1892684b8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 18 13:15:00 CST 2016, time=2016-07-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1999571, encodeId=4d2a19995e137, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 27 20:15:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720062, encodeId=7b931e2006261, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Jan 25 20:15:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849514, encodeId=937018495140f, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Oct 18 21:15:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010330, encodeId=5bb12010330f1, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Wed Aug 31 05:15:00 CST 2016, time=2016-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806035, encodeId=2c0118060359f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 02 12:15:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892684, encodeId=957a1892684b8, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 18 13:15:00 CST 2016, time=2016-07-18, status=1, ipAttribution=)]

相关资讯

Medicine:年轻缺血性卒中和先前存在精神障碍

先前研究表明精神障碍比如:严重抑郁症,双相障碍以及酒精使用障碍与缺血性卒中的发生相关。然而,在精神障碍和年轻患者卒中之间的关系研究的较少。应用台湾国家健康保险数据库,招募了1998年到2011年间,18到45岁缺血性卒中患者,8252名年龄和性别相匹配的对照组。确定先前存在精神障碍的受试者。校正先前存在生理疾病和人口学数据。缺血性卒中的患者先前存在精神障碍的风险较高,包括双相障碍(OR: 2.23

Atherosclerosis:空腹及餐后甘油三酯和颈动脉内膜厚度的关系

背景:颈总动脉内膜厚度(CCA-IMT)是动脉粥样硬化的一种检测指标。甘油三酯在CCA-IMT中的作用尚有争议。研究人员旨在确定是否空腹及餐后甘油三酯与CCA-IMT相关。 方法:招募2009年1月到2014年1月期间参与柏林“Cream和Sugar”研究中的急性缺血性卒中患者,并对其进行颈动脉超声检测的患者。第一次缺血性卒中后,对患者进行3-7天口服糖和甘油三酯耐受实验。根据甘油三酯的代谢情况,

Geriatr Gerontol Int:卒中前痴呆对其缺血性卒中的影响

目的:这篇研究的主要目的是确定卒中前痴呆(PSD)是否影响老年缺血性卒中患者的短期功能预后。方法:对老年缺血性卒中患者进行回顾性病例对照研究。应用功能独立测量量表(FIM)对患者入院和出院时进行功能预后评估。应用t检验,卡方检验,多次线性回归以及logistics回归分析数据。结果:急性缺血性卒中患者919名,其中11.5%诊断为PSD。与非PSD患者相比,PSD患者,存活时间较短,女性患者比例较

Neurology:对存在未破裂颅内动脉瘤的缺血性卒中进行全身溶栓是安全的

目的:研究人员进行中心研究和综合meta分析,旨在确定存在未破裂颅内动脉瘤(UIA)的急性缺血性卒中(AIS)患者静脉溶栓(IVT)的安全性。方法:研究人员分析了4年间4个卒中中心进行IVT治疗的AIS患者的数据。入院期间,所有患者常规行CT或MRI检查。基于神经影像学报告确定存在UIA。症状性脑内出血(sICH)由ICH的影像学证据和NIHSS分数增加超过4分确定。根据PRISMA指南对存在未破

BMJ Open:抗癫痫药与缺血性卒中和心肌梗死发生的关系

目的:肝酶诱导的抗癫痫药物(AEDs)通过诱导细胞色素P450增加血浆中的脂质及其他动脉粥样硬化标志物,因此可能会增加血管事件的发生。研究人员根据AED代谢的酶特性旨在评估其对缺血性卒中和心肌梗死(MI)发生的风险。设计:病例对照分析的群体队列研究。英国临床实践研究数据链中的650个普通医生的医业。受试者:招募1990年1月到2013年4月间252407名应用AED的患者,患者年龄在18岁以上。每

J Am Heart Assoc: 预测缺血性卒中后的再入院模型

背景:减少患者再入院是卒中护理的主要改革部分。当前的再入院预测模型准确性较差,并且仅局限于急性入院的数据。研究人员假设基于全国范围内的急性期后护理数据库的患者因素可能改善预测模型。方法:应用2008年的国际疾病分类(第九版)确诊并筛选出大于65岁缺血性卒中患者。应最小数据集(MDS)对患者急性期后护理进行综合评估。应用logistic回归建立风险校正再入院模型。协变量为MDS变量。结果:在3917

Baidu
map
Baidu
map
Baidu
map